Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology appointed Dr. Suzanne Topalian to its Board of Directors, effective October 27, 2026. Dr. Topalian is a prominent figure in cancer immunotherapy, holding key positions at Johns Hopkins University. Her expertise is expected to benefit Vir's strategic direction and innovation in the biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Suzanne Topalian brings extensive expertise in cancer immunotherapy.
  • Her appointment strengthens Vir Biotechnology's board.
  • Topalian's leadership at Johns Hopkins enhances the company's credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine* and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins. “Su

Frequently Asked Questions

Who is Suzanne Topalian?

Suzanne Topalian is a leading expert in cancer immunotherapy at Johns Hopkins.

When will Dr. Topalian join the board?

Dr. Topalian's appointment is effective October 27, 2026.

What positions does Dr. Topalian hold?

She is the Bloomberg-Kimmel Professor and Associate Director at Johns Hopkins.

How does her appointment benefit Vir?

Her expertise enhances Vir's strategic direction in cancer therapies.

ShareAdd on Google
Tags: VIR Vir Biotechnology Suzanne Topalian cancer immunotherapy Board of Directors Johns Hopkins
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$529M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →